Theranos Investigation Continues As COO Out At Firm
The Theranos investigation is likely in the deliberative stage, determining what corrective action might be taken for a company that operated on the edge. In this environment a sacrifice might have occurred as the chief operating officer and one of the original architects of the company’s system leaves the firm. One of the primary Theranos executives targeted by regulators with a potential ban from the medical testing industry, COO Ramesh (Sunny) Balwani, is departing the blood testing firm. The company is under both regulatory and criminal investigations related to its pin-prick blood testing methodology and the generally secretive methods that...
This content is exclusively for paying members of Hedge Fund Alpha
Gain Exclusive Access to the Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha Get Started Now with a FREE 7-Day Trial🔻If you are a current Hedge Fund Alpha member and are having an account error please clear cache and cookies. If that does not work, email [email protected] or click Chat. |
